GE Healthcare’s Neurology Bet: Can The Icometrix Acquisition Unlock The Alzheimer’s Diagnosis Market?

GE HealthCare has deepened its push into precision medicine with a strategic agreement to acquire icometrix, a Belgium-based firm specializing in AI-powered brain imaging analysis. The deal, announced in September 2025, highlights GE HealthCare’s increasing commitment to neurological diagnostics and advanced clinical decision support tools. Although the financial details remain undisclosed and the transaction is still subject to regulatory clearance, GEHC intends to fund the acquisition entirely with cash on hand. This move follows the company’s broader efforts to fortify its position in digital health and diagnostics, especially as it seeks to capture growth in the Alzheimer’s and neurological disease space. Icometrix’s flagship platform, icobrain, is already providing radiologists and neurologists with automated, quantifiable insights into brain disorders such as multiple sclerosis, dementia, and traumatic brain injury. By bringing icometrix into the fold, GE HealthCare aims to enhance its precision care strategy, leveraging AI to offer more consistent and early-stage diagnoses for complex neurological conditions.